{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:10Z","timestamp":1791873430430,"version":"4.3.4"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The combination of atezolizumab and bevacizumab (A + B) is the new standard of care for the systemic first-line treatment of hepatocellular carcinoma (HCC). However, up to now there are only few data on the safety and efficacy of A + B in real life. We included patients with advanced HCC treated with A + B as first-line therapy at four cancer centers in Germany and Austria between December 2018 and August 2021. Demographics, overall survival (OS), and adverse events were assessed until 15 September 2021. We included 66 patients. Most patients had compensated cirrhosis (n = 34; 52%), while Child\u2013Pugh class B cirrhosis was observed in 23 patients (35%), and class C cirrhosis in 5 patients (8%). The best responses included a complete response (CR) in 7 patients (11%), a partial response (PR) in 12 patients (18%), stable disease (SD) in 22 patients (33%), and progressive disease in 11 patients (17%). The median progression-free (PFS) survival was 6.5 months, while the median overall survival (OS) was not reached in this cohort (6-month OS: 69%, 12-month OS: 60%, 18-month OS: 58%). Patients with viral hepatitis seemed to have a better prognosis than patients with HCC of non-viral etiology. The real-world PFS and OS were comparable to those of the pivotal IMBRAVE trial, despite including patients with worse liver function in this study. We conclude that A + B is also highly effective in a real-life setting, with manageable toxicity, especially in patients with compensated liver disease. In patients with compromised liver function (Child B and C), the treatment showed low efficacy and, therefore, it should be well considered before administration to these patients.<\/jats:p>","DOI":"10.3390\/cancers14071722","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:40:14Z","timestamp":1648590014000},"page":"1722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers"],"prefix":"10.3390","volume":"14","author":[{"given":"Vera","family":"Himmelsbach","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-0974","authenticated-orcid":false,"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-Von Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-8833","authenticated-orcid":false,"given":"Friedrich","family":"Sinner","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-Von Guericke University Hospital, 39120 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Zimpel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Johannes Gutenberg University, 55131 Mainz, Germany"},{"name":"Department of Medicine I, University Medical Centre Schleswig-Holstein, Campus L\u00fcbeck, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens U.","family":"Marquardt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Johannes Gutenberg University, 55131 Mainz, Germany"},{"name":"Department of Medicine I, University Medical Centre Schleswig-Holstein, Campus L\u00fcbeck, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany"},{"name":"University Cancer Center Frankfurt, University Hospital Frankfurt, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Waidmann","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany"},{"name":"University Cancer Center Frankfurt, University Hospital Frankfurt, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-9910","authenticated-orcid":false,"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany"},{"name":"University Cancer Center Frankfurt, University Hospital Frankfurt, 60590 Frankfurt, Germany"},{"name":"Frankfurt Cancer Institute, Goethe University Frankfurt\/Main, 60590 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A Randomized, Multi-Center Phase III Study of Nivolumab (NIVO) vs. Sorafenib (SOR) as First-Line (1L) Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (AHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-Reported Outcomes with Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Giannini, E.G., Aglitti, A., Borzio, M., Gambato, M., Melandro, F., Morisco, F., Ponziani, F.R., and Rendina, M. (2019). Overview of Immune Checkpoint Inhibitors Therapy Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 11.","DOI":"10.3390\/cancers11111689"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"052","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (MRECIST) Assessment for Hepatocellular Carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_10","unstructured":"US Department of Health and Human Services (2009). Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events v4.0 (CTCAE), National Institutes of Health, National Cancer Institute."},{"key":"ref_11","unstructured":"National Cancer Institute US (2017). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ix186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: Efficacy and Safety Results from a Ph III Study Evaluating Atezolizumab (Atezo) + Bevacizumab (Bev) vs Sorafenib (Sor) as First Treatment (Tx) for Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000513486","article-title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","volume":"10","author":"Qin","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/hepr.13712","article-title":"Does Immune Checkpoint Inhibitor Exhibit Limited Efficacy against Non-Viral Hepatocellular Carcinoma?: A Review of Clinical Trials","volume":"52","author":"Eso","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Iwamoto, H., Shimose, S., Noda, Y., Shirono, T., Niizeki, T., Nakano, M., Okamura, S., Kamachi, N., Suzuki, H., and Sakai, M. (2021). Initial Experience of Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 13.","DOI":"10.3390\/cancers13112786"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ando, Y., Kawaoka, T., Kosaka, M., Shirane, Y., Johira, Y., Miura, R., Murakami, S., Yano, S., Amioka, K., and Naruto, K. (2021). Early Tumor Response and Safety of Atezolizumab plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers, 13.","DOI":"10.3390\/cancers13163958"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1464","DOI":"10.1002\/cnr2.1464","article-title":"Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Early Clinical Experience","volume":"5","author":"Hiraoka","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hayakawa, Y., Tsuchiya, K., Kurosaki, M., Yasui, Y., Kaneko, S., Tanaka, Y., Ishido, S., Inada, K., Kirino, S., and Yamashita, K. (2021). Early Experience of Atezolizumab plus Bevacizumab Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Investig. New Drugs, 1\u201311.","DOI":"10.21203\/rs.3.rs-794293\/v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hepr.13693","article-title":"Early Response and Safety of Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet IMbrave150 Eligibility Criteria","volume":"51","author":"Sho","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e000042","DOI":"10.1136\/esmoopen-2016-000042","article-title":"Cancer and Liver Cirrhosis: Implications on Prognosis and Management","volume":"1","author":"Pinter","year":"2016","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1216","DOI":"10.1002\/onco.13776","article-title":"Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates","volume":"26","author":"Shek","year":"2021","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00432-018-2780-8","article-title":"Feasibility and Safety of Nivolumab in Advanced Hepatocellular Carcinoma: Real-Life Experience from Three German Centers","volume":"145","author":"Finkelmeier","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for Advanced Hepatocellular Carcinoma: A Focus on Special Subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicentre Real-World Cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hep.30212","article-title":"Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma","volume":"69","author":"Inada","year":"2019","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.726008","article-title":"Incidence and Risk of Hypertension in Cancer Patients Treated with Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/7\/1722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:45:11Z","timestamp":1760136311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/7\/1722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cancers14071722"],"URL":"https:\/\/doi.org\/10.3390\/cancers14071722","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]}}}